AF2150

antibody from R&D Systems

Targeting: C5 C5a, C5b, CPAMD4

Western blot (Data presented on provider website)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

AF2150

Provider

R&D Systems

Product name

Mouse Complement Component C5a Antibody

Antibody type

Polyclonal

Description

Antigen Affinity-purified. Detects mouse Complement Component C5a in direct ELISAs and Western blots. In direct ELISAs and Western blots (non-reducing conditions), approximately 50% cross-reactivity with recombinant human Complement Component C5a is observed.

Reactivity

Mouse

Host

Goat

Conjugate

Unconjugated

Antigen sequence

P06684


Isotype

IgG

Vial size

100 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation.

Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009 Aug;9(8):1784-95

---

Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.

Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS
Journal of immunology (Baltimore, Md. : 1950) 2007 Nov 1;179(9):5793-802

---

Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.

Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS
Journal of immunology (Baltimore, Md. : 1950) 2007 Nov 1;179(9):5793-802

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Chemotaxis Induced by Complement Component C5a and Neutralization by Mouse Complement Component C5a Antibody. Recombinant Mouse Complement Component C5a (Catalog # 2150-C5) chemoattracts the J774A.1 mouse reticulum cell sarcoma macrophage cell line in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Complement Component C5a (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Complement Component C5a Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2150). The ND₅₀ is typically 0.6-3.0 µg/mL.

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

N-Acetyl-beta -D-Glucosaminidase Release Induced by Complement Component C5a and Neutralization by Mouse Complement Component C5a Antibody. Recombinant Mouse Complement Component C5a (Catalog # 2150-C5) inducesN-acetyl- beta -D-glucosaminidase release in the the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line in a dose-dependent manner (orange line). N-Acetyl- beta -D-Glucosaminidase Release elicited by Recombinant Mouse Complement Component C5a (100 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Complement Component C5a Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2150). The ND₅₀ is typically 0.3-1.8 μg/mL in the presence of cytochalasin-B.